Skip to main content
Required Health Expenditure

Required Health Expenditure

  • Between 2007 and 2018, almost US$ 7.3 billion was invested in basic research and product development for malaria.

  • The malaria R&D funding landscape has been led by investment in:
    • Drugs (US$ 2.6 billion, 36% of malaria funding between 2007 and 2018)

    • Basic research (US$ 1.9 billion, 26%)

    • Vaccines R&D (US$ 1.8 billion, 25%)

    • Vector control products (US$ 453 million, 6.2%)

    • Vector control diagnostic (US$ 185 million, 2.5%)

  • Over the period 2010–2020, international sources provided 69% of the total funding for malaria control and elimination, led by the United States of America (USA), the United Kingdom of Great Britain and Northern Ireland (UK), and France.
  • Total funding for malaria control and elimination in 2020 was estimated at US$ 3.3 billion, compared with US$ 3.0 billion in 2019 and US$ 2.7 billion in 2018. The amount invested in 2020 falls short of the US$ 6.8 billion estimated to be required, leaving a funding gap of at least US$ 3.5 billion.

  • Of the US$ 3.3 billion invested in 2020, more than US$ 2.2 billion came from international funders. The highest contributions in 2020 were from the USA, which provided a total of US$ 1.3 billion, followed by Germany and the UK with about US$ 0.2 billion each, and then US$ 0.1 billion from France and Japan. Of the US$ 3.3 billion invested in 2020, nearly US$ 1.4 billion (42%) was channelled through the Global Fund – an increase of about US$ 0.2 billion since 2019.